Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 15/20 | 0.81 |
| ▸ | CHRM1 | P11229 | 15/20 | 0.81 |
| ▸ | CHRM3 | P20309 | 15/20 | 0.81 |
| ▸ | CHRM2 | P08172 | 14/20 | 0.81 |
| ▸ | CHRM4 | P08173 | 14/20 | 0.81 |
| ▸ | DRD2 | P14416 | 10/20 | 0.81 |
| ▸ | DRD4 | P21917 | 10/20 | 0.81 |
| ▸ | DRD3 | P35462 | 10/20 | 0.81 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.81 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.81 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.81 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.81 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.81 |
| ▸ | HTR7 | P34969 | 5/20 | 0.63 |
| ▸ | HTR1A | P08908 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100746 | 0.90 | CHRM2 (1.00) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL29400334 | 0.90 | CHRM2 (1.00) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL4104781 | 0.83 | CHRM1 (0.74) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL4095785 | 0.81 | CHRM1 (0.67) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL7476444 | 0.81 | DRD2 (0.63) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL2491730 | 0.79 | HTR7 (0.62) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL2149137 | 0.79 | CHRM1 (0.64) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL23339326 | 0.78 | HTR7 (0.63) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL15396975 | 0.78 | HTR7 (0.63) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL4103777 | 0.78 | CHRM1 (0.75) | CHRM5CHRM1CHRM3CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009520-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2008-01-10 | — | — | US | claimed |
| US-20060205785-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-09-14 | — | — | US | claimed |
| EP-1432420-B1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARM INC (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20100216840-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20080070948-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080009520-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-7300928-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7291611-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7273857-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-20060258707-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-11-16 | — | — | US | disclosed |
| US-20060205785-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-09-14 | — | — | US | disclosed |
| US-20060199799-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-09-07 | — | — | US | disclosed |
| US-7087593-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060025402-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-02-02 | — | — | US | disclosed |
| US-6951849-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-20030100545-A1 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS, INC. | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070948-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | CHRM4, CHRM1, CHRM2 | CHRM5 5/4885CHRM1 2/4885CHRM3 4/4885 |
| US-20030100545-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM5, CHRM1 | CHRM5 2/4885CHRM1 3/4885CHRM3 4/4885 |
| US-20060258707-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM1, CHRM2 | CHRM5 5/4885CHRM1 2/4885CHRM3 4/4885 |
| US-20100216840-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | CHRM4, CHRM1, CHRM2 | CHRM5 5/4885CHRM1 2/4885CHRM3 4/4885 |
| US-20060025402-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM1, CHRM2 | CHRM5 5/4885CHRM1 2/4885CHRM3 4/4885 |
| US-20080009520-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | CHRM4, CHRM1, CHRM2 | CHRM5 5/4885CHRM1 2/4885CHRM3 4/4885 |
| US-20060199799-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM1, CHRM2 | CHRM5 5/4885CHRM1 2/4885CHRM3 4/4885 |
| US-20060205785-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM1, CHRM2 | CHRM5 5/4885CHRM1 2/4885CHRM3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.